Comparative Pharmacology
Head-to-head clinical analysis: AMOXICILLIN AND CLAVULANATE POTASSIUM versus CLOXAPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXICILLIN AND CLAVULANATE POTASSIUM versus CLOXAPEN.
AMOXICILLIN AND CLAVULANATE POTASSIUM vs CLOXAPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Clavulanate potassium is a beta-lactamase inhibitor that irreversibly inactivates beta-lactamase enzymes, preventing degradation of amoxicillin.
Cloxapen inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBPs involved in the transpeptidation step of peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
500 mg amoxicillin/125 mg clavulanate orally every 8 hours or 875 mg amoxicillin/125 mg clavulanate orally every 12 hours. For severe infections: 875 mg amoxicillin/125 mg clavulanate orally every 8 hours or 1000 mg amoxicillin/62.5 mg clavulanate extended-release orally every 12 hours.
Oral: 250-500 mg every 6 hours. IV: 1-2 g every 4-6 hours.
None Documented
None Documented
Amoxicillin: ~1-1.5 hours; Clavulanate: ~1 hour. Prolonged in renal impairment.
Terminal elimination half-life 1.5-2 hours; prolonged to 2.5-4 hours in severe renal impairment; clinical context: requires frequent dosing in normal renal function
Renal: ~50-70% amoxicillin unchanged; ~25-40% clavulanate as metabolites. Fecal: minimal. Biliary: minor.
Renal 70-80% as unchanged drug and active metabolite; biliary 5-10%; fecal <5%
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic